Format

Send to

Choose Destination
Clin Endocrinol (Oxf). 2017 Mar;86(3):384-387. doi: 10.1111/cen.13239. Epub 2016 Oct 7.

Endocannabinoid receptor blockade increases vascular endothelial growth factor and inflammatory markers in obese women with polycystic ovary syndrome.

Author information

1
Department of Academic Endocrinology, Diabetes and Metabolism, University of Hull, Hull, UK.
2
Sidra Research Centre, Doha, Qatar.
3
Department of Obstetric Ultrasound, Hull & East Yorkshire Women's & Children's Hospital, Hull, UK.
4
Weill Cornell Medicine Qatar, Doha, Qatar.

Abstract

CONTEXT:

Animal studies suggest that cannabinoid receptor-1 (CB-1) blockade reduces inflammation and neovascularization by decreasing vascular endothelial growth factor (VEGF) levels associated with a reduction in inflammatory markers, thereby potentially reducing cardiovascular risk.

OBJECTIVE:

To determine the impact of CB1 antagonism by rimonabant on VEGF and inflammatory markers in obese PCOS women.

DESIGN:

Randomized, open-labelled parallel study.

SETTING:

Endocrinology outpatient clinic in a referral centre.

SUBJECTS:

Twenty patients with PCOS (PCOS) and biochemical hyperandrogenaemia with a body mass index of ≥30 kg/m2 were recruited. Patients were randomized to 1·5 g daily of metformin or 20 mg daily of rimonabant.

MAIN OUTCOME MEASURES:

Post hoc review to detect VEGF and pro-inflammatory cytokines TNF-α, IL-1β, IL-1ra, IL-2, IL6, IL-8, IL-10 and MCP-1 before and after 12 weeks of treatment.

RESULTS:

After 12 weeks of rimonabant treatment, there was a significant increase in VEGF (99·2 ± 17·6 vs 116·2 ± 15·8 pg/ml, P < 0·01) and IL-8 (7·4 ± 11·0 vs 18·1 ± 13·2 pg/ml, P < 0·05) but not after metformin (VEGF P = 0·7; IL-8 P = 0·9). There was no significant difference in the pro-inflammatory cytokines TNF-α, IL-1β, IL-1ra, IL-2, IL6, IL-8, IL-10 and MCP-1 following either treatment.

CONCLUSION:

This study suggests that rimonabant CB-I blockade paradoxically raised VEGF and the cytokine IL-8 in obese women with PCOS that may have offset the potential benefit associated with weight loss.

PMID:
27651218
DOI:
10.1111/cen.13239
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center